Pilot Study of the Effect of GM-CSF on Macrophages in Incompletely Resected or Recurrent Ependymoma
Clinical Trial Information
Trial Contact: El-Shami, Jessica; Leffin, Melissa; Spinelli, Jennifer
IRB No: 16.030.02
Protocol Abbrev: 13-0133
Principal Investigator: Amy A Smith, MD
Age Group: Pediatric
Secondary Protocol No: 13-033
Therapies Involved: Medication
This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients with an ependymoma.
-Age > 12 months and < 21 years at the time of study enrollment.
-Patients must be one of the following:
*Newly diagnosed with posterior fossa ependymoma with a subtotal resection at initial surgery. These
patients will be eligible for stratum 1.
*Be in first relapse of their posterior fossa ependymoma. These patients will be eligible for stratum 2.
-Histologically confirmed diagnosis of intracranial ependymoma .